Synnerva

Company Overview

Snapshot

Founded in July 2019 by Vladimir Ritter, Synnerva operated with 1–10 employees. The company raised $500,000 across one funding round from one investor, NGT3. Synnerva ceased operations in March 2024.

Business overview

Synnerva was an early-stage pharmaceutical company focused on developing and commercializing proprietary central nervous system (CNS) drug compositions. The company's core technology involved a platform designed to significantly reduce effective doses and eliminate side effects of CNS drugs. This method combined generic, FDA-approved APIs with stimulators of vagal afferents, leading to synergistic enhancement of therapeutic effects without side effects. Synnerva's portfolio included improved compositions for drugs like levodopa, targeting the Health Tech & Life Sciences sector, specifically.

Company Intelligence Q&A

What is Synnerva's operational status?

Synnerva is currently non-active, having ceased operations in March 2024.

When was Synnerva founded?

Synnerva was founded in July 2019.

Who founded Synnerva?

Synnerva was founded by Vladimir Ritter, who also served as CEO and CTO.

What was Synnerva's primary focus?

Synnerva focused on the development and commercialization of proprietary central nervous system (CNS) drug compositions designed to reduce effective doses and eliminate side effects.

What was the total capital raised by Synnerva?

Synnerva raised a total of $500,000 across one funding round.